129 related articles for article (PubMed ID: 1911358)
1. Natural-killer cell activity and cytogenetic response in chronic myelogenous leukemia treated with alpha-interferon.
Meseri A; Delwail V; Mahon FX; Pelletier D; Guilhot F; Brizard A; Gombert J; Tanzer J; Goube de Laforest P
Br J Haematol; 1991 Aug; 78(4):585-6. PubMed ID: 1911358
[No Abstract] [Full Text] [Related]
2. Endogenous lymphokine activated killer cell activity and cytogenetic response in chronic myelogenous leukaemia treated with alpha-interferon.
Meseri A; Delwail V; Brizard A; Lecron JC; Pelletier D; Guilhot F; Tanzer J; Goube de Laforest P
Br J Haematol; 1993 Feb; 83(2):218-22. PubMed ID: 8457470
[TBL] [Abstract][Full Text] [Related]
3. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service.
Kantarjian HM; Smith TL; O'Brien S; Beran M; Pierce S; Talpaz M
Ann Intern Med; 1995 Feb; 122(4):254-61. PubMed ID: 7825760
[TBL] [Abstract][Full Text] [Related]
4. Persistence of BCR/ABL mRNA-expressing bone-marrow cells in patients with chronic myelogenous leukemia in complete cytogenetic remission induced by interferon-alpha therapy.
Eberlé F; Toiron Y; Camerlo J; Lafage M; Sainty D; Arnoulet C; Raineri V; Gabert J; Maraninchi D; Mannoni P
Leuk Lymphoma; 1995 Jun; 18(1-2):153-7. PubMed ID: 8580818
[TBL] [Abstract][Full Text] [Related]
5. Management of resistance to lymphoblastoid interferon alpha in chronic myeloid leukaemia.
Barton LM; Green AR
Br J Haematol; 1998 Dec; 103(4):1208-9. PubMed ID: 9886345
[No Abstract] [Full Text] [Related]
6. Interferon therapy for Ph1-positive chronic myelogenous leukaemia patients relapsing after T-cell depleted allogeneic bone marrow transplantation.
Arcese W; Mauro FR; Screnci M; Alimena G; Lo Coco F; Iori AP; de Cuia MR; Fazi P; Montefusco E; Mandelli F
Eur J Cancer; 1991; 27 Suppl 4():S28-30. PubMed ID: 1799471
[No Abstract] [Full Text] [Related]
7. Prolonged hematological remission by mitoxantrone and interferon--alpha-2b in a child with resistant Philadelphia chromosome-positive chronic myelogenous leukemia.
Duru F; Tuncer M; Hiçsönmez G
Eur J Haematol; 1993 Sep; 51(3):173-4. PubMed ID: 8405332
[No Abstract] [Full Text] [Related]
8. Combined therapy interferon and chemotherapy in chronic myelogenous leukemia.
Guilhot F; Dreyfus B; Desmarest MC; Giraud C; Huret JL; Brizard A; Tanzer J
Nouv Rev Fr Hematol (1978); 1989; 31(2):171-3. PubMed ID: 2771633
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.
Niederle N; Kloke O; Wandl UB; Becher R; Moritz T; Opalka B
Leuk Lymphoma; 1993 Jan; 9(1-2):111-9. PubMed ID: 8477190
[TBL] [Abstract][Full Text] [Related]
10. Effects of alpha-interferon on MHC unrestricted cytotoxicity in chronic myelogenous leukemia.
Meseri-Delwail A; Delwail V; Brizard A; Goube de Laforest P; Guilhot F; Lecron JC
Biotechnol Ther; 1994; 5(1-2):47-57. PubMed ID: 7703832
[TBL] [Abstract][Full Text] [Related]
11. Crescentic glomerulonephritis during treatment with interferon-alpha 2b.
Durand JM; Retornaz F; Cretel E; Kaplanski G; Soubeyrand J
Am J Hematol; 1995 Feb; 48(2):140-1. PubMed ID: 7847342
[No Abstract] [Full Text] [Related]
12. Interferon alpha in the therapy of CML.
Talpaz M; Kantarjian H; Kurzrock R; Gutterman JU
Br J Haematol; 1991 Oct; 79 Suppl 1():38-41. PubMed ID: 1931707
[TBL] [Abstract][Full Text] [Related]
13. Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle.
Pigneux A; Devergie A; Pochitaloff M; Rio B; Archimbaud E; Cahn JY; Leblond V; Michallet M; Jouet JP; Guilhot F
Bone Marrow Transplant; 1995 Jun; 15(6):819-24. PubMed ID: 7581075
[TBL] [Abstract][Full Text] [Related]
14. Hypertriglyceridemia may be severe in CML patients treated with interferon-alpha.
Peñarrubia MJ; Steegmann JL; Lavilla E; Casado F; Requena MJ; Picó M; Arranz R; Fernández-Rañada JM
Am J Hematol; 1995 Jul; 49(3):240-1. PubMed ID: 7604817
[TBL] [Abstract][Full Text] [Related]
15. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
[TBL] [Abstract][Full Text] [Related]
16. Alpha-2a-interferon administration and Fc gamma RIII expression on neutrophils from chronic myeloid leukemia.
Carulli G; Papineschi F; Azzarà A; Ambrogi F
Leuk Res; 1996 Jul; 20(7):627-8. PubMed ID: 8795698
[No Abstract] [Full Text] [Related]
17. [Cellular immunotherapy in chronic myeloid leukemia].
Fernández MN
Sangre (Barc); 1998 Apr; 43(2):164-70. PubMed ID: 9656778
[No Abstract] [Full Text] [Related]
18. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients.
Talpaz M; Kantarjian H; Kurzrock R; Trujillo JM; Gutterman JU
Ann Intern Med; 1991 Apr; 114(7):532-8. PubMed ID: 2001086
[TBL] [Abstract][Full Text] [Related]
19. Treatment of chronic myeloid leukemia with interferon alpha (Roferon): results of the Israeli Study Group on CML.
Shtalrid M; Lugassy G; Rosensaft J; Berrebi A
Leuk Lymphoma; 1993; 11 Suppl 1():193-7. PubMed ID: 8251895
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies.
Freund M; von Wussow P; Diedrich H; Eisert R; Link H; Wilke H; Buchholz F; LeBlanc S; Fonatsch C; Deicher H
Br J Haematol; 1989 Jul; 72(3):350-6. PubMed ID: 2765403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
